AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

BRAIN Biotech AG

Earnings Release Apr 30, 2025

6314_rns_2025-04-30_67215bd7-2fab-4ac9-9872-be812968582e.html

Earnings Release

Open in Viewer

Opens in native device viewer

News Details

Ad-hoc | 30 April 2025 17:54

BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

BRAIN Biotech AG / Key word(s): Preliminary Results/Change in Forecast

BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

30-Apr-2025 / 17:54 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


BRAIN Biotech AG reports preliminary Q2 figures and forecasts a more conservative development for the second half of the fiscal year 2024/25

Zwingenberg, Germany, 30 April 2024 – BRAIN Biotech AG (ISIN DE0005203947; “ BRAIN ” or “ Company ”) today reports preliminary Q2 figures for the financial year 2024/25 with Q2 revenues of EUR 12.12 million and an adjusted EBITDA of minus EUR 0.36 million. The publication of the comprehensive half year reporting for 31 March 2025 (6M) and the analyst call will take place as previously scheduled on May 28 th , 2025.

Due to the overall weaker economic environment and strong USD currency fluctuations the Company now forecasts full-year 2024/25 revenues for the core segment BRAINBiocatalysts to be around the level of last year and therefore below the original guidance. The guidance for the adjusted EBITDA margin in the segment BRAINBiocatalysts and the guidance for the segment BRAINBioIncubator remains unchanged.

Notifying person:

Martina Schuster

BRAIN Biotech AG

– Investor Relations –

Darmstädter Str. 34-36

64673 Zwingenberg

Deutschland

www.brain-biotech-group.com

Investor Relations Office

Tel.: +49-(0)-6251-9331-0

Fax: +49-(0)-6251-9331-11

E-Mail: [email protected]

End of Inside Information


30-Apr-2025 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.

Archive at www.eqs-news.com


Language: English
Company: BRAIN Biotech AG
Darmstädter Straße 34-36
64673 Zwingenberg
Germany
Phone: +49 (0) 62 51 / 9331-0
Fax: +49 (0) 62 51 / 9331-11
E-mail: [email protected]
Internet: www.brain-biotech.com
ISIN: DE0005203947
WKN: 520394
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange
EQS News ID: 2128270
End of Announcement EQS News Service

2128270  30-Apr-2025 CET/CEST

Talk to a Data Expert

Have a question? We'll get back to you promptly.